These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 12940594

  • 1. Pharmacokinetic-pharmacodynamic interrelationships of intravenous and oral levosimendan in patients with severe congestive heart failure.
    Põder P, Eha J, Sundberg S, Antila S, Heinpalu M, Loogna I, Planken U, Rantanen S, Lehtonen L.
    Int J Clin Pharmacol Ther; 2003 Aug; 41(8):365-73. PubMed ID: 12940594
    [Abstract] [Full Text] [Related]

  • 2. Pharmacodynamics and pharmacokinetics of oral levosimendan and its metabolites in patients with severe congestive heart failure: a dosing interval study.
    Põder P, Eha J, Sundberg S, Antila S, Heinpalu M, Loogna I, Planken U, Rantanen S, Lehtonen L.
    J Clin Pharmacol; 2004 Oct; 44(10):1143-50. PubMed ID: 15342615
    [Abstract] [Full Text] [Related]

  • 3. Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals.
    Sundberg S, Antila S, Scheinin H, Häyhä M, Virtanen M, Lehtonen L.
    Int J Clin Pharmacol Ther; 1998 Dec; 36(12):629-35. PubMed ID: 9876999
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan.
    Antila S, Kivikko M, Lehtonen L, Eha J, Heikkilä A, Pohjanjousi P, Pentikäinen PJ.
    Br J Clin Pharmacol; 2004 Apr; 57(4):412-5. PubMed ID: 15025738
    [Abstract] [Full Text] [Related]

  • 5. Orally available levosimendan dose-related positive inotropic and lusitropic effect in conscious chronically instrumented normal and heart failure dogs.
    Masutani S, Cheng HJ, Hyttilä-Hopponen M, Levijoki J, Heikkilä A, Vuorela A, Little WC, Cheng CP.
    J Pharmacol Exp Ther; 2008 Apr; 325(1):236-47. PubMed ID: 18174383
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure.
    Kivikko M, Antila S, Eha J, Lehtonen L, Pentikäinen PJ.
    Int J Clin Pharmacol Ther; 2002 Oct; 40(10):465-71. PubMed ID: 12395979
    [Abstract] [Full Text] [Related]

  • 7. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.
    Licata G, Di Pasquale P, Parrinello G, Cardinale A, Scandurra A, Follone G, Argano C, Tuttolomondo A, Paterna S.
    Am Heart J; 2003 Mar; 145(3):459-66. PubMed ID: 12660669
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of the clinical, hemodynamic and neurohormonal response to levosimendan administration in decompensated heart failure patients. One-month follow-up.
    Sargento L, Brito D, Matias JS, Madeira H.
    Rev Port Cardiol; 2007 Mar; 26(7-8):717-26. PubMed ID: 17939581
    [Abstract] [Full Text] [Related]

  • 9. Treatment of experimental verapamil poisoning with levosimendan utilizing a rodent model of drug toxicity.
    Graudins A, Najafi J, Rur-SC MP.
    Clin Toxicol (Phila); 2008 Jan; 46(1):50-6. PubMed ID: 17926153
    [Abstract] [Full Text] [Related]

  • 10. Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience.
    Parle NM, Thomas MD, Dembo L, Best M, Driscoll GO.
    Heart Lung Circ; 2008 Jun; 17(3):206-10. PubMed ID: 18242130
    [Abstract] [Full Text] [Related]

  • 11. The contractility enhancing effect of the calcium sensitiser levosimendan is not attenuated by carvedilol in healthy subjects.
    Lehtonen L, Sundberg S.
    Eur J Clin Pharmacol; 2002 Oct; 58(7):449-52. PubMed ID: 12389066
    [Abstract] [Full Text] [Related]

  • 12. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure.
    Kivikko M, Antila S, Eha J, Lehtonen L, Pentikäinen PJ.
    J Clin Pharmacol; 2002 Jan; 42(1):43-51. PubMed ID: 11808823
    [Abstract] [Full Text] [Related]

  • 13. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
    Cleland JG, Nikitin N, McGowan J.
    Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409
    [Abstract] [Full Text] [Related]

  • 14. The effect of levosimendan during long-term amiodarone treatment in dogs.
    Papp JG, Pollesello P, Varró A, Végh A, Udvary E.
    Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):27-32. PubMed ID: 16867167
    [Abstract] [Full Text] [Related]

  • 15. Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure.
    Drakos SG, Kanakakis JV, Nanas S, Bonios M, Kaldara E, Katsaros F, Pantsios C, Nanas JN.
    J Cardiovasc Pharmacol; 2009 Feb; 53(2):157-61. PubMed ID: 19188832
    [Abstract] [Full Text] [Related]

  • 16. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F.
    Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [Abstract] [Full Text] [Related]

  • 17. Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone.
    Nanas JN, Papazoglou PP, Terrovitis JV, Kanakakis J, Dalianis A, Tsolakis E, Tsagalou EP, Agrios N, Christodoulou K, Anastasiou-Nana MI.
    Am J Cardiol; 2004 Nov 15; 94(10):1329-32. PubMed ID: 15541261
    [Abstract] [Full Text] [Related]

  • 18. The hemodynamic and pharmacokinetic interactions between chronic use of oral levosimendan and digoxin in patients with NYHA Classes II-III heart failure.
    Harjola VP, Oikarinen L, Toivonen L, Jurkko R, Puttonen J, Sarapohja T, Sundberg S, Nieminen MS.
    Int J Clin Pharmacol Ther; 2008 Aug 15; 46(8):389-99. PubMed ID: 18793580
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone.
    Nanas JN, Papazoglou P, Tsagalou EP, Ntalianis A, Tsolakis E, Terrovitis JV, Kanakakis J, Nanas SN, Alexopoulos GP, Anastasiou-Nana MI.
    Am J Cardiol; 2005 Mar 15; 95(6):768-71. PubMed ID: 15757608
    [Abstract] [Full Text] [Related]

  • 20. The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies.
    Lilleberg J, Ylönen V, Lehtonen L, Toivonen L.
    Scand Cardiovasc J; 2004 May 15; 38(2):80-4. PubMed ID: 15204232
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.